Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39

Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors

Genentech, a member of the Roche, announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized medicine entrectinib shrank tumors in more than half of people with neurotrophic tropomyosin receptor kinase fusion-positive solid tumors. Objective responses to entrectinib were seen across 10 different solid tumor types, including in people with and without central nervous system metastases at baseline. Importantly, entrectinib shrank tumors that had spread to the brain in over half of people, with more than a quarter of these people having a complete response. The safety profile of entrectinib was consistent with that seen in previous analyses. Entrectinib has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or have no acceptable standard therapies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible. Genentech plans to submit results from these integrated analyses to global health authorities for the treatment of NTRK fusion-positive solid tumors and ROS1-positive NSCLC.

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:53
03/25/19
03/25
13:53
03/25/19
13:53
Hot Stocks
Apple introduces Apple Arcade game subscription service »

Apple announced Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:51
03/25/19
03/25
13:51
03/25/19
13:51
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade pricing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:50
03/25/19
03/25
13:50
03/25/19
13:50
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.08

-3.03 (-1.59%)

13:48
03/25/19
03/25
13:48
03/25/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:47
03/25/19
03/25
13:47
03/25/19
13:47
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:46
03/25/19
03/25
13:46
03/25/19
13:46
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

RLGY

Realogy

$11.82

0.02 (0.17%)

13:45
03/25/19
03/25
13:45
03/25/19
13:45
Options
Realogy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
03/25/19
03/25
13:45
03/25/19
13:45
General news
Euro$ interest rate futures are cracking higher »

Euro$ interest rate…

AAPL

Apple

$188.55

-2.56 (-1.34%)

, GS

Goldman Sachs

$188.87

0.3 (0.16%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Apple partners with Goldman Sachs, Mastercard to launch Apple Card »

Apple (AAPL) announced…

AAPL

Apple

$188.55

-2.56 (-1.34%)

GS

Goldman Sachs

$188.87

0.3 (0.16%)

MA

MasterCard

$229.47

-1.3 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 15

    Apr

  • 03

    Jun

  • 25

    Jun

AAPL

Apple

$188.55

-2.56 (-1.34%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple aanounces Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

CCL

Carnival

$56.60

-0.13 (-0.23%)

, MKC

McCormick

$142.96

0.66 (0.46%)

13:42
03/25/19
03/25
13:42
03/25/19
13:42
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.60

-0.13 (-0.23%)

MKC

McCormick

$142.96

0.66 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

RHT

Red Hat

$181.76

0.13 (0.07%)

13:42
03/25/19
03/25
13:42
03/25/19
13:42
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.87

-2.24 (-1.17%)

13:40
03/25/19
03/25
13:40
03/25/19
13:40
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

13:39
03/25/19
03/25
13:39
03/25/19
13:39
Conference/Events
Cantor Fitzgerald tech services analyst to hold analyst/industry conference call »

Tech Services Analyst…

AAPL

Apple

$188.31

-2.8 (-1.47%)

13:39
03/25/19
03/25
13:39
03/25/19
13:39
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple Card…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.39

-2.72 (-1.42%)

13:38
03/25/19
03/25
13:38
03/25/19
13:38
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says physical card…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.78

-2.33 (-1.22%)

13:37
03/25/19
03/25
13:37
03/25/19
13:37
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple Card…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

OESX

Orion Energy

$0.91

0.017 (1.90%)

13:36
03/25/19
03/25
13:36
03/25/19
13:36
Hot Stocks
Orion CEO says focused on Enterprise grade LED lighting »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

AAPL

Apple

$188.96

-2.15 (-1.13%)

, MA

MasterCard

$230.00

-0.77 (-0.33%)

13:36
03/25/19
03/25
13:36
03/25/19
13:36
Hot Stocks
Breaking Hot Stocks news story on Apple, MasterCard »

Apple partered with…

AAPL

Apple

$188.96

-2.15 (-1.13%)

MA

MasterCard

$230.00

-0.77 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

  • 25

    Jun

EIGR

Eiger BioPharmaceuticals

$13.60

-0.31 (-2.23%)

13:35
03/25/19
03/25
13:35
03/25/19
13:35
Hot Stocks
Eiger announces Phase 2 PREVENT study met primary efficacy endpoint »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$189.34

-1.77 (-0.93%)

, GS

Goldman Sachs

$188.80

0.23 (0.12%)

13:35
03/25/19
03/25
13:35
03/25/19
13:35
Hot Stocks
Breaking Hot Stocks news story on Apple, Goldman Sachs »

Apple partnered with…

AAPL

Apple

$189.34

-1.77 (-0.93%)

GS

Goldman Sachs

$188.80

0.23 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 15

    Apr

  • 03

    Jun

AAPL

Apple

$189.25

-1.86 (-0.97%)

13:34
03/25/19
03/25
13:34
03/25/19
13:34
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Card has no late…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$189.29

-1.82 (-0.95%)

13:33
03/25/19
03/25
13:33
03/25/19
13:33
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Daily Cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$189.33

-1.78 (-0.93%)

13:32
03/25/19
03/25
13:32
03/25/19
13:32
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Card will give 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$189.76

-1.35 (-0.71%)

13:31
03/25/19
03/25
13:31
03/25/19
13:31
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Card has Daily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.